Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways.

@article{Chou2011ReversibleIO,
  title={Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways.},
  author={Tsui-Fen Chou and Steve J. Brown and Dimitriy Minond and Brian E. Nordin and Kelin Li and Amanda C. Jones and Peter P. Chase and Patrick R. Porubsky and Brian M Stoltz and Frank J. Schoenen and Matthew P. Patricelli and Peter S. Hodder and Harvey M. Rosen and Raymond J Deshaies},
  journal={Proceedings of the National Academy of Sciences of the United States of America},
  year={2011},
  volume={108 12},
  pages={
          4834-9
        }
}
A specific small-molecule inhibitor of p97 would provide an important tool to investigate diverse functions of this essential ATPase associated with diverse cellular activities (AAA) ATPase and to evaluate its potential to be a therapeutic target in human disease. We carried out a high-throughput screen to identify inhibitors of p97 ATPase activity. Dual-reporter cell lines that simultaneously express p97-dependent and p97-independent proteasome substrates were used to stratify inhibitors that… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 117 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 58 REFERENCES

Combination therapy of bortezomib with novel targeted agents: An emerging treatment strategy

  • JJ Wright
  • Clin Cancer Res
  • 2010
2 Excerpts

Similar Papers

Loading similar papers…